Drug Profile

Meloxicam injection - Azurity Pharmaceuticals

Alternative Names: XIFYRM

Latest Information Update: 07 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Azurity Pharmaceuticals
Class 2 ring heterocyclic compounds; Amides; Analgesics; Anti-inflammatories; Antipyretics; Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Small molecules; Thiazines; Thiazoles
Mechanism of Action Cyclo-oxygenase 2 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Registered Pain

Most Recent Events

10 Jun 2025 Azurity Pharmaceuticals announces intention to launch Meloxicam injection for Pain
10 Jun 2025 Meloxicam injection has boxed warning for risk of serious Cardiovascular and Gastrointestinal events
06 May 2025 Registered for Pain in USA (IV)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com